Literature DB >> 15531718

Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes.

Johannes Klein1, Sören Westphal, Daniel Kraus, Britta Meier, Nina Perwitz, Volker Ott, Mathias Fasshauer, H Harald Klein.   

Abstract

Metformin is an anti-diabetic drug with anorexigenic properties. The precise cellular mechanisms of its action are not entirely understood. Adipose tissue has recently been recognized as an important endocrine organ that is pivotal for the regulation of insulin resistance and energy homeostasis. Due to its thermogenic capacity brown adipose tissue contributes to the regulation of energy metabolism and is an attractive target tissue for pharmacological approaches to treating insulin resistance and obesity. Leptin is the prototypic adipocyte-derived hormone inducing a negative energy balance. We investigated effects of metformin on adipocyte metabolism, signalling, and leptin secretion in a brown adipocyte model. Metformin acutely stimulated p44/p42 mitogen-activated protein (MAP) kinase in a dose- (3.2-fold at 1 mmol/l, P< 0.05) as well as time-dependent (3.8-fold at 5 min, P< 0.05) manner. This stimulation was highly selective since phosphorylation of intermediates in the stress kinase, janus kinase (JAK)-signal transducer and activator of transcription (STAT), and phosphatidylinositol (PI) 3-kinase signalling pathways such as p38 MAP kinase, STAT3, and Akt was unaltered. Furthermore, chronic metformin treatment for 12 days dose-dependently inhibited leptin secretion by 35% and 75% at 500 mumol/l and 1 mmol/l metformin respectively (P< 0.01). This reduction was not caused by alterations in adipocyte differentiation. Moreover, the impairment in leptin secretion by metformin was reversible within 48 h after removal of the drug. Pharmacological inhibition of p44/p42 MAP kinase prevented the metformin-induced negative effect on leptin secretion. Taken together, our data demonstrate direct acute effects of metformin on adipocyte signalling and endocrine function with robust inhibition of leptin secretion. They suggest a selective molecular mechanism that may contribute to the anorexigenic effect of this antidiabetic compound.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15531718     DOI: 10.1677/joe.1.05646

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  15 in total

Review 1.  Signalling mechanisms linking hepatic glucose and lipid metabolism.

Authors:  M O Weickert; A F H Pfeiffer
Journal:  Diabetologia       Date:  2006-05-23       Impact factor: 10.122

Review 2.  Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes.

Authors:  Ebenezer A Nyenwe; Terri W Jerkins; Guillermo E Umpierrez; Abbas E Kitabchi
Journal:  Metabolism       Date:  2011-01       Impact factor: 8.694

3.  Prenatal androgenization of female mice programs an increase in firing activity of gonadotropin-releasing hormone (GnRH) neurons that is reversed by metformin treatment in adulthood.

Authors:  Alison V Roland; Suzanne M Moenter
Journal:  Endocrinology       Date:  2010-12-15       Impact factor: 4.736

4.  A fatty meal aggravates apnea and increases sleep in patients with obstructive sleep apnea.

Authors:  Georgia Trakada; Paschalis Steiropoulos; Paul Zarogoulidis; Evangelia Nena; Nikolaos Papanas; Efstratios Maltezos; Demosthenes Bouros
Journal:  Sleep Breath       Date:  2013-04-24       Impact factor: 2.816

5.  Exenatide and metformin express their anti-inflammatory effects on human monocytes/macrophages by the attenuation of MAPKs and NFκB signaling.

Authors:  Łukasz Bułdak; Grzegorz Machnik; Rafał Jakub Bułdak; Krzysztof Łabuzek; Aleksandra Bołdys; Bogusław Okopień
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-07-16       Impact factor: 3.000

6.  Metformin protects rat hepatocytes against bile acid-induced apoptosis.

Authors:  Titia E Woudenberg-Vrenken; Laura Conde de la Rosa; Manon Buist-Homan; Klaas Nico Faber; Han Moshage
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

7.  Metformin suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-+Leprdb/+Leprdb mice.

Authors:  Tomohiko Ohno; Masahito Shimizu; Yohei Shirakami; Atsushi Baba; Takahiro Kochi; Masaya Kubota; Hisashi Tsurumi; Takuji Tanaka; Hisataka Moriwaki
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

8.  Serum leptin changes with metformin treatment in polycystic ovarian syndrome: correlation with ovulation, insulin and testosterone levels.

Authors:  Prerna Upadhyaya; H S Rehan; Vikas Seth
Journal:  EXCLI J       Date:  2011-02-24       Impact factor: 4.068

Review 9.  Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases.

Authors:  Christoffer Clemmensen; Brian Finan; Timo D Müller; Richard D DiMarchi; Matthias H Tschöp; Susanna M Hofmann
Journal:  Nat Rev Endocrinol       Date:  2019-02       Impact factor: 43.330

10.  Metformin; A character actor in the leptin story!

Authors:  Manash P Baruah; Sanjay Kalra; Salam Ranabir
Journal:  Indian J Endocrinol Metab       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.